Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To investigate the effect of growth hormone replacement on inflammatory and other cardiovascular risk factors.

Why It Was Studied

Growth hormone replacement may affect cardiovascular risk.

Inflammation plays an important role in atherosclerosis, and inflammatory markers are predictive of cardiovascular events.

Who Took Part

According to the abstract, 40 men were involved.

PubMed indexes the participants as adults and middle-aged adults, men only.

40 men with adult-onset growth hormone deficiency.

How the Study Was Run

In design terms this was a randomized, single-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the men, was kept unaware of whether Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was given.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

Anthropometric, hemoglobin A1c, and central fat values were assessed every 6 months.

Levels of glucose, insulin, insulin-like growth factor I, and lipids were measured at 1, 3, 6, 12, and 18 months.

C-reactive protein, serum amyloid polypeptide A, inteleukin-6, and lipoprotein(a) levels were determined at baseline and 6 and 18 months.

What Was Measured

Topics PubMed links to this paper include Adipose Tissue, Analysis of Variance, Anthropometry, Blood Glucose, C-Reactive Protein, Cardiovascular Diseases and Hormone Replacement Therapy.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 40 men.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (Annals of internal medicine), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.